INVIVYD, INC. Operating Income
INVIVYD, INC. (IVVD) reported Operating Income of -$45.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- INVIVYD, INC. operating income (loss) for the quarter ending 2026-06-30 was -$45.82M.
- INVIVYD, INC. operating income (loss) for the quarter ending 2026-03-31 was -$43.14M.
- INVIVYD, INC. operating income (loss) for the quarter ending 2025-12-31 was -$12.55M.
- INVIVYD, INC. operating income (loss) for the quarter ending 2025-09-30 was -$11.02M.
- INVIVYD, INC. operating income (loss) for fiscal 2025 was -$55.56M.
- INVIVYD, INC. operating income (loss) for fiscal 2024 was -$176.88M.
- INVIVYD, INC. operating income (loss) for fiscal 2023 was -$212.76M.
- INVIVYD, INC. operating income (loss) for fiscal 2022 was -$248.03M.
| Period end | Operating Income (Loss) 1 month | Operating Income (Loss) 3 month | Operating Income (Loss) 4 month | Operating Income (Loss) 6 month | Operating Income (Loss) 7 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$45.82M 10-Q · filed 2026-08-13 | -$88.96M 10-Q · filed 2026-08-13 | -$101.51M derived: sum of 3 quarters · filed 2026-08-13 | -$112.53M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$43.14M 10-Q · filed 2026-05-14 | -$55.69M derived: sum of 2 quarters · filed 2026-05-14 | -$66.71M derived: sum of 3 quarters · filed 2026-05-14 | -$81.77M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$12.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$23.58M derived: sum of 2 quarters · filed 2026-03-05 | -$38.64M derived: sum of 3 quarters · filed 2026-08-13 | -$55.56M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$11.02M 10-Q · filed 2025-11-06 | -$26.08M derived: sum of 2 quarters · filed 2026-08-13 | -$43.01M 10-Q · filed 2025-11-06 | -$62.23M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | -$15.06M 10-Q · filed 2026-08-13 | -$31.98M 10-Q · filed 2026-08-13 | -$51.21M derived: sum of 3 quarters · filed 2026-08-13 | -$113.52M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$16.92M 10-Q · filed 2026-05-14 | -$36.15M derived: sum of 2 quarters · filed 2026-05-14 | -$98.46M derived: sum of 3 quarters · filed 2026-05-14 | -$147.71M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$19.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$81.54M derived: sum of 2 quarters · filed 2026-03-05 | -$130.79M derived: sum of 3 quarters · filed 2026-03-05 | -$176.88M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$62.31M 10-Q · filed 2025-11-06 | -$111.56M derived: sum of 2 quarters · filed 2025-11-06 | -$157.65M 10-Q · filed 2025-11-06 | -$234.40M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$49.25M 10-Q · filed 2025-08-14 | -$95.34M 10-Q · filed 2025-08-14 | -$172.09M derived: sum of 3 quarters · filed 2025-08-14 | -$215.15M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$46.09M 10-Q · filed 2025-05-15 | -$122.84M derived: sum of 2 quarters · filed 2025-05-15 | -$165.90M derived: sum of 3 quarters · filed 2025-05-15 | -$219.78M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$76.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$119.81M derived: sum of 2 quarters · filed 2025-03-20 | -$173.69M derived: sum of 3 quarters · filed 2025-03-20 | -$212.76M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | -$43.06M 10-Q · filed 2024-11-14 | -$96.94M derived: sum of 2 quarters · filed 2024-11-14 | -$136.01M 10-Q · filed 2024-11-14 | -$184.22M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$53.88M 10-Q · filed 2024-08-14 | -$92.95M 10-Q · filed 2024-08-14 | -$141.16M derived: sum of 3 quarters · filed 2024-08-14 | -$188.49M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | -$39.07M 10-Q · filed 2024-05-09 | -$87.28M derived: sum of 2 quarters · filed 2024-05-09 | -$134.61M derived: sum of 3 quarters · filed 2024-05-09 | -$186.36M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$48.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$95.54M derived: sum of 2 quarters · filed 2024-03-28 | -$147.29M derived: sum of 3 quarters · filed 2024-03-28 | -$248.03M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$47.33M 10-Q · filed 2023-11-09 | -$99.08M derived: sum of 2 quarters · filed 2023-11-09 | -$199.82M 10-Q · filed 2023-11-09 | -$282.91M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-06-30 | -$51.75M 10-Q · filed 2023-08-10 | -$152.49M 10-Q · filed 2023-08-10 | -$235.58M derived: sum of 3 quarters · filed 2024-02-09 | -$296.00M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-03-31 | -$100.74M 10-Q · filed 2023-05-11 | -$183.83M derived: sum of 2 quarters · filed 2024-02-09 | -$244.25M derived: sum of 3 quarters · filed 2024-02-09 | -$288.94M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2021-12-31 | -$83.09M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | -$143.51M derived: sum of 2 quarters · filed 2024-02-09 | -$188.20M derived: sum of 3 quarters · filed 2024-02-09 | -$226.91M 8-K · filed 2024-02-09 | |||
| 2021-09-30 | -$60.42M 10-Q · filed 2022-11-10 | -$105.11M derived: sum of 2 quarters · filed 2022-11-10 | -$143.82M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | -$44.69M 10-Q · filed 2022-08-15 | -$83.40M 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | -$38.71M 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | -$65.33M 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | -$48.01M 10-Q · filed 2021-11-15 | -$48.11M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | -$98.00K 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |